-- This report provides a comprehensive overview of the size of the regenerative medicine market, segmentation of the market (stem cells, tissue engineering and CAR-T therapy), key players and the vast potential of therapies that are in clinical trials. The analysis indicates that the global Regenerative Medicine Market was worth $28 billion in 2018 and will grow to over $81 billion by 2023, with a CAGR of 23.3% between this time frame. Within this market, the stem cell industry will grow significantly at a CAGR of over x% and reach $x billion by 2023. Tissue engineering is forecast to grow at a CAGR of x% to 2023 and potentially reach $x billion. This report describes the evolution of such a huge market in 15 chapters supported by over 350 tables and figures in 700 pages.
• An overview of regenerative medicine that includes: stem cells, allogenic and autogenic cells, umbilical cord blood banking, tissue engineering and CAR T therapies.
• Global regenerative medicine market, global breakdown, application breakdown and leading market players
• Detailed account of the stem cell industry market by geography, indication and company profiles
• Profiles, marketed/pipeline products, financial analysis and business strategy of the major companies in this space
• Focus on current trends, business environment, pipeline products, clinical trials, and future market forecast for regenerative medicine
• Insight into the challenges faced by stakeholders, particularly about the success vs. failure ratios in developing regenerative medicine drugs and therapies.
• Insight into the biobanking industry globally and its impact on the overall market
• Description and data for the prevalence of disease types that are addressed by regenerative medicine, stem cells, tissue engineering and CAR-T therapies
• Financial market forecast through 2023 with CAGR values of all market segments outlined in the objective
• SWOT analysis of the global market
• Geographical analysis and challenges within key topographies including the USA, Japan, South Korea, China and Europe
Get Free Sample Copy of this Research Report at https://www.reportsnreports.com/contacts/requestsample.aspx?name=974420
Executive Summary
Regenerative medicine’s main objective is to heal and replace organs/cells that have been damaged by age, trauma or disease. Congenital defects can also be addressed with regenerative medicine. Therefore, it’s market encompasses dermal wounds, cardiovascular disease, specific cancer types and organ replacement. To that end, regenerative medicine is a broader field and manipulates the body’s immune system and regeneration potential to achieve its requirement. Financially speaking, investment into this space is dominated by grants, private investors and publicly traded stocks. Looking forward, the regenerative medicine market is promising for a number of robust reasons including:
• Increasing number of potentially successful clinical trials
• Increasing number of mergers and acquisitions
• High unmet need in many indications
• Global penetration, especially in Japan will boost the market
Of course restrictions to this market include strict regulations in certain geographies, and also the level of investment required to support R&D, clinical research, trials and commercialization. Reimbursement strategies are also paramount to success of the overall space.
There are over 700 regenerative medicine companies globally at present, that all together have a $x billion market cap. At present the total regenerative medicine market has more than 500 products commercialized. The regenerative medicine market encompasses a number of key technology submarkets including:
• Cell therapy including stem cells
• Tissue Engineering
• Biomaterials
• BioBanking
Reconstructive surgeries for bones and joints is the mainstay of the regenerative medicine market. Geographically speaking, due to the dominance of the bone and joint reconstruction market, the US has the biggest space. This is followed by Europe. However, due to recent positive legislation in Japan and Europe, the stem cell arena will grow more substantially in these regions over the next five years. By 2023, it is possible that Europe will surpass the US market with respect to stem cell applications, and this will become more likely if the Trump Administration restricts legislation and funding.
Get Discount on this Research Report at https://www.reportsnreports.com/contacts/discount.aspx?name=974420
Market Applications & Opportunities for Regenerative Therapies
Regenerative medicine, including cellular and gene therapies will have a significant impact on the expenditure of payers, once reimbursement schemes are optimized. To that end a number of conditions that regenerative medicine tackles is synonymous with an aging population such as
• Cardiovascular diseases & stroke
• Diabetes
• Inflammatory and immune diseases
• Wound healing and soft tissue regeneration
• Neurodegenerative diseases e.g., ALS, Alzheimer’s and Parkinson’s
• Spinal cord injury
• Musculoskeletal disorders
• Ocular disease
Global Financial Landscape
The last few years have been busy for regeneration medicine, cellular therapeutics and the gene therapy industry, with high investment from pharma giants such as Eli Lilly, BMS, Astra Zeneca and Sanofi. Company partnerships were also in motion that included Kite Pharma and Bluebird/Five Prime, Juno and Fate Therapeutics/ Editas Medicine. One of the highlights was the $x billion, four year deal between CRISPR Technologies and Vertex which indicated that gene editing technologies are cutting edge.
Stem Cell Market Analysis & Forecast to 2023
Direct Purchase of this Research Report at https://www.reportsnreports.com/purchase.aspx?name=974420
Tissue Engineering Market Analysis and Forecast to 2023
Biobanking Market Analysis
CAR-T Industry
The CAR-T industry is addressing unmet needs in specific relapsed cancers, however does early clinical trial data support a blockbuster status for this upcoming therapy? Some patients do indeed show long term activity and high remission rates, but there is a large proportion of patients with toxicities such as cytokine release syndrome and neurotoxicity. The main players within the CAR-T market are Juno Therapeutics, Kite Pharma, Novartis and Cellectis. The market is moving ahead, backed by years of R&D, from both academia and industry, investors capitol and small clinical studies. From 2017, forecasts that CAR T therapy will become more streamlined, with faster manufacturing times as advances in technologies take hold and clinical trials provide more robust evidence that this immunotherapy is robust. These factors, plus strategies to reduce adverse reactions and toxicities and larger players like Novartis taking stage will push CAR T therapy ahead. However, recent deaths in the Juno ROCKET trial are creating questions amongst investors. How will the CAR T space influence the total immunotherapy industry going forward? This comprehensive report scrutinizes the total market and provides cutting-edge insights and analysis.
Companies Mentioned
• Astellas Institute for Regenerative Medicine (Ocata Therapeutics)
• AstraZeneca
• Athersys
• Baxter International (Baxalta, Shire)
• Bayer
• Caladrius Biosciences (NeoStem)
• Celgene
• CHA Biotech
• Chimerix
• Cynata Therapeutics
• Cytori Therapeutics
• Eisai
• Genzyme (Sanofi)
• GSK
• Janssen
• InCyte Corp
• MedImmune
• MEDIPOST
• Merck
• Mesoblast
• Millennium Pharmaceutical
• NuVasive
• Osiris Therapeutics
• Plasticell
• Pluristem Therapeutics
• Pfizer
• SanBio Current Stem Cell Trials
• Seattle Genetics Current Stem Cell Trials
• StemCells Inc
• STEMCELL Technologies
• Takara Bio
• Teva Current Stem Cell Trials
• Tigenix
Contact Info:
Name: Vishal
Email: Send Email
Organization: ReportsnReports
Website: https://www.reportsnreports.com/reports/974420-global-regenerative-medicine-market-analysis-forecast-to-2021-stem-cells-tissue-engineering-biobanking-car-t-industries.html
Release ID: 527950
Google
RSS